NuVasive Ups Bet on Orthobiologics

Alex Lukianov, NuVasive Chair and CEO, is hoping to fill a gap in the $1 billion orthobiologics market between BMPs (bone morphogenic proteins) and commodity synthetic and allograft bone extenders.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button